[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA93709C2 - 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions - Google Patents

12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions

Info

Publication number
UA93709C2
UA93709C2 UAA200812523A UAA200812523A UA93709C2 UA 93709 C2 UA93709 C2 UA 93709C2 UA A200812523 A UAA200812523 A UA A200812523A UA A200812523 A UAA200812523 A UA A200812523A UA 93709 C2 UA93709 C2 UA 93709C2
Authority
UA
Ukraine
Prior art keywords
dodecanol
imidazolyl
preparation
pharmaceutical compositions
compound
Prior art date
Application number
UAA200812523A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Дитер Мюллер-Энок
Томас Гайгнер
Original Assignee
Дитер Мюллер-Энок
Томас Гайгнер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дитер Мюллер-Энок, Томас Гайгнер filed Critical Дитер Мюллер-Энок
Publication of UA93709C2 publication Critical patent/UA93709C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to novel therapeutic agents, in particular to compound 12-imidazolyl-1-dodecanol or a pharmaceutically acceptable salt thereof and to use thereof for the preparation of pharmaceutical composition.
UAA200812523A 2006-04-28 2007-04-27 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions UA93709C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006019906A DE102006019906A1 (en) 2006-04-28 2006-04-28 Use of compounds comprising a hydrophilic tail linked via a hydrocarbon group to a group comprising a carbon or heteroatom free electron pair and/or pi electrons to prepare pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UA93709C2 true UA93709C2 (en) 2011-03-10

Family

ID=38462536

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200812523A UA93709C2 (en) 2006-04-28 2007-04-27 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions

Country Status (15)

Country Link
US (1) US8153676B2 (en)
EP (1) EP2023911B1 (en)
JP (1) JP2009535309A (en)
KR (1) KR101113436B1 (en)
CN (1) CN101478960B (en)
AU (1) AU2007246023B2 (en)
BR (1) BRPI0710796A2 (en)
CA (1) CA2650577C (en)
DE (2) DE102006019906A1 (en)
HK (1) HK1134902A1 (en)
IL (1) IL194961A0 (en)
MX (1) MX2008013829A (en)
RU (3) RU2477275C1 (en)
UA (1) UA93709C2 (en)
WO (1) WO2007124734A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007051339A1 (en) 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Use of an aliphatic or aromatic hydrocarbon compound for manufacturing a preparation to prevent or treat dyslipidemia
DE102010012235A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh New substituted imidazole compounds, useful e.g. to treat cancer, pathological consequences of alcohol abuse, viral hepatitis, acute and chronic pancreatitis, toxic renal disease and hepatic insulin resistance in diabetes mellitus
DE102010012225A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Cosmetics, useful for skin care and for prophylaxis and treatment of photodamaged skin and age-damaged skin, preferably for prophylactic treatment of wrinkles and skin roughness, comprise 12-imidazolyl-1-dodecanol
DE102010012234A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmaceutical combination preparation, useful to treat cancer, preferably to reduce e.g. nephrotoxicity of cisplatin or platinum complex analog, comprises 12-imidazolyl-1-dodecanol and cisplatin or a platinum complex analog
DE102010012223A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmaceutical preparation, useful for the treatment of autoimmune disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Crohn's disease or ulcerative colitis, comprises 12-imidazolyl-1-dodecanol
DE102010012232A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases
DE102010012224A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmaceutical preparation, useful for the intravenous treatment of paracetamol intoxication, comprises 12-imidazolyl-1-dodecanol or its salt
DE102010012233A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh New substituted imidazole compounds, useful e.g. to treat cancer, pathological consequences of alcohol abuse, viral hepatitis, acute and chronic pancreatitis, toxic renal disease and hepatic insulin resistance in diabetes mellitus
DE102010012226A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmaceutical combination preparation, useful to improve the effect of ursodeoxycholic acid, which is useful to treat e.g. nonalcoholic-steatohepatitis and viral hepatitis, comprises 12-imidazolyl-1-dodecanol and ursodeoxycholic acid
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
DE102011112103A1 (en) 2011-09-02 2013-03-07 Acrovis Biostructures Gmbh Composition, useful as antineoplastic drug, comprises a cyclodextrin complex with 12-imidazolyl-1-dodecanol
DE102012018052A1 (en) 2011-09-21 2013-03-21 Acrovis Biostructures Gmbh Pharmaceutical combination preparation
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN105541727B (en) * 2016-01-15 2018-01-30 徐州医学院 A kind of lipid molecular, its preparation method and its application in tumour radiotherapy medicine for having radio therapy sensitization function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016452B (en) * 1978-02-18 1982-07-21 Kissei Pharmaceutical Imidazole compounds
JPS591415A (en) * 1982-06-28 1984-01-06 Mochida Pharmaceut Co Ltd Remedy for circulatory disease
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
US5436269A (en) 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
US20020183333A1 (en) * 2000-03-29 2002-12-05 Shah Sudhir V. Compositions and methods for chemotherapy having reduced nephrotoxicity
DE102004052697A1 (en) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmaceutical preparations for the treatment of alcohol abuse, hepatitis, pancreatitis, Alzheimer's disease, Parkinson's disease, diabetes, toxic kidney disease, reperfusion damage, arteriosclerosis and as an antidote to environmental toxins and drug intoxication

Also Published As

Publication number Publication date
RU2446801C2 (en) 2012-04-10
BRPI0710796A2 (en) 2011-08-09
CN101478960B (en) 2012-06-06
US20090191262A1 (en) 2009-07-30
CA2650577C (en) 2013-01-15
KR20090023590A (en) 2009-03-05
CA2650577A1 (en) 2007-11-08
RU2477275C1 (en) 2013-03-10
AU2007246023B2 (en) 2012-08-16
WO2007124734A3 (en) 2008-02-07
MX2008013829A (en) 2009-04-03
CN101478960A (en) 2009-07-08
HK1134902A1 (en) 2010-05-20
RU2008146974A (en) 2010-06-10
DE112007001669A5 (en) 2009-04-16
EP2023911A2 (en) 2009-02-18
DE102006019906A1 (en) 2007-10-31
AU2007246023A1 (en) 2007-11-08
JP2009535309A (en) 2009-10-01
IL194961A0 (en) 2009-08-03
US8153676B2 (en) 2012-04-10
RU2009113390A (en) 2010-10-20
WO2007124734A2 (en) 2007-11-08
KR101113436B1 (en) 2012-03-16
EP2023911B1 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
UA96449C2 (en) Stable laquinimod preparations
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MY146969A (en) Dpp iv inhibitor formulations
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
TW200639156A (en) New compounds
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
TW200745122A (en) New compounds I
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
TW200734334A (en) Treatment of substance abuse
ZA200806778B (en) N-Hydroxyacrylamide compounds
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
MX2009013501A (en) Piperidine compounds and uses thereof.
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
TW200626158A (en) Naphthaline derivatives
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200745133A (en) New compounds II
TW200800993A (en) Organic compounds
GB0615105D0 (en) Novel compounds